ASENAPINE MALEATE Suppliers: Contract Manufacturers and API/Intermediate Players
Last updated: April 23, 2026
Which companies supply asenapine maleate as an API or drug substance?
Asenapine maleate is commercially sourced through branded and generic manufacturing supply chains. The most relevant supplier universe falls into two buckets: drug-substance (API) producers and finished-dose (FDF) manufacturers that can supply through regulated channels.
Who are the contract-manufacturing and supply-chain companies used for asenapine products?
The typical procurement route for asenapine maleate is through established CRO-to-CMO and API supply networks that already support controlled global registrations. The companies below are repeatedly present in the asenapine supply chain for API and/or solid oral dosage manufacturing and related intermediates.
API / drug substance supply ecosystem (often through regional GMP sites)
Alkermes (originator; development and manufacturing ecosystem for asenapine)
Generic API and intermediate suppliers that produce asenapine maleate drug substance via specialized GMP routes for active pharmaceutical ingredients used in antipsychotics
Finished-dose supply ecosystem (FDF CMOs and integrated manufacturers)
Brand and generic FDF manufacturers producing asenapine sublingual tablets (key marketed form factor), using asenapine maleate drug substance sourced from approved suppliers
What product form and specification drives supplier selection for asenapine maleate?
Supplier capability is constrained by the dosage form and control strategy for asenapine sublingual delivery, which is sensitive to:
Particle size and polymorphic control of asenapine maleate API
Purity profile (impurities and solvent residues aligned to compendial and registration specifications)
Moisture control and packaging compatibility for sublingual tablets
Dose uniformity and dissolution performance for solid oral products
Asenapine maleate market buyers typically demand these supplier assurances
Procurement for asenapine maleate API and/or drug product commonly requires:
GMP manufacture in inspected facilities (FDA, EMA, or equivalent regulator)
DMF/CEP coverage where applicable for API and key intermediates
Batch traceability and qualification packages
Ongoing stability programs that match the marketed shelf-life for sublingual tablets
Supplier due-diligence checklist tied to asenapine maleate
Screening area
What buyers verify for asenapine maleate
Regulatory status
DMF/CEP or equivalent dossier availability for the API
Quality system
GMP compliance and recent regulator inspection outcomes
Analytical control
Impurity panel, residual solvents, assay range, and dissolution-linked release tests
Formulation fit
Capability to support the sublingual tablet process (if supplying FDF)
Supply reliability
Multi-site redundancy and capacity for scheduled campaigns
Key takeaways
Asenapine maleate supply is dominated by GMP-regulated API and FDF networks aligned to the sublingual tablet performance envelope.
Supplier selection is driven by API polymorph/particle control, impurity and residual solvent control, and stability-dosed manufacturing fit for sublingual formulations.
In practice, buyers source through originator-aligned ecosystems (Alkermes) and generic/regulatory-approved API and CMO/FDF supply chains already supporting asenapine product registrations.
FAQs
Is asenapine maleate supplied mainly as API or as finished-dose product?
It is supplied in both forms, but procurement often starts with API/drug substance for formulation partnerships or with FDF supply for commercial readiness.
Why does the sublingual dosage form affect supplier choice?
Sublingual tablets require tighter control of API physical attributes and formulation process parameters linked to dissolution and uniformity.
What documents matter most when buying asenapine maleate API?
Buyers typically require dossier support (DMF/CEP or equivalent), GMP evidence, and full analytical release packages.
What quality attributes are most critical for asenapine maleate?
Purity/impurity profile, residual solvents, assay, and physical properties (including polymorph/particle size) that impact downstream performance.
Who typically sits at the center of the asenapine supply chain?
The originator ecosystem (notably Alkermes) plus approved generic API and regulated FDF manufacturing networks.
References
[1] Alkermes. Company information and product manufacturing ecosystem for antipsychotic assets including asenapine (company materials).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
